Empirical antifungal therapy in selected patients with persistent febrile neutropenia

Bone Marrow Transplantation

Volumn 45, Issue 1, 2010, Pages 159-164

  Aguilar Guisado, M ^a   Espigado, I ^a   Cordero, E ^a   Noguer, M ^a   Parody, R ^a   Pachon J ^a   Cisneros, J M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

EAT; Haematological malignancies; IFI; PFN; SCT

Indexed keywords

AMPHOTERICIN; CASPOFUNGIN; FLUCONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; TREATMENT INDICATION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; FEMALE; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MYCOSES; NEUTROPENIA; PROSPECTIVE STUDIES; SEPSIS; SHOCK, SEPTIC;

EID: 75149154262     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.125     Document Type: Article

References (21)

1. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
2. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-111.
3. EORTC international antimicrobial therapy cooperative group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668-672.
4. Cisneros JM, Espigado I, Rivero A, Lozano de León F, Parra J, Collado AR et al. Sociedad Andaluza de Enfermedades Infecciosas. Empirical antifungal therapy in selected patients with persistent fever and neutropenia. Enferm Infecc Microbiol Clin 2005; 23: 609-614.
5. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771. (Pubitemid 29114295)
6. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
7. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2002; 346: 225-234. (Pubitemid 34438861)
8. Cherif H, Kalin M, Bjorkholm M. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment? Eur J Haematol 2006; 77: 288-292.
9. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E et al. Galactomannan and computed tomography- based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-1250.
10. Marchetti O, Cordonnier C, Calandra T. Empirical antifungal therapy in neutropenic patients with cancer. Eur J Cancer 2007; 5: 32-59.
11. Ascioglu S, Rex JH, De Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
12. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-1075.
13. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-1610.
14. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415. (Pubitemid 34851833)
15. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ et al. Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.
16. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-1079.
17. Maschmeyer G, Link H, Hiddeman W, Meyer P, Helmerking M, Eisenmann E et al. Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomised multicenter study. Cancer 1994; 73: 2296-2304.
18. Talbot GH, Huang A, Provencher M. Invasive aspergillus rhinosinusitis in patients with acute leukaemia. Rev Infect Dis 1991; 13: 219-232.
19. Hagensee ME, Bauwens JE, Kjos B, Bowden RA. Brain abscess following marrow transplantation. Bone Marrow Transplant 1999; 23: 1167-1176.
20. Thaler M, Pastakia B, Shawker TH, O'Learry T, Pizzo A. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Inter Med 1988; 108: 88-100.
21. Radhakrishnan R, Donato ML, Prieto VG, Mays SR, Raad II, Kuerer HM. Invasive cutaneous fungal infections requiring radical resection in cancer patients undergoing chemotherapy. J Surg Oncol 2004; 88: 21-26.